NovaBay Pharmaceuticals (NBY) 10-Q 9 May 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 07, 2024
Document Information [Line Items]
Entity Central Index Key	0001389545
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	001-33678
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	68-0454536
Entity Address, Address Line One	2000 Powell Street, Suite 1150
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	899-8800
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	NBY
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,831,410

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
ASSETS
Cash and cash equivalents	$ 1,823	$ 2,924
Accounts receivable, net of allowance for credit losses ($3 at March 31, 2024 and December 31, 2023)	734	680
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($229 and $264 at March 31, 2024 and December 31, 2023, respectively)	663	564
Prepaid expenses and other current assets	371	256
Current assets, discontinued operations	0	2,730
Total current assets	3,591	7,154
Operating lease right-of-use assets	1,212	1,296
Property and equipment, net	77	87
Other assets	477	478
Other assets, discontinued operations	0	19
TOTAL ASSETS	5,357	9,034
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	1,117	906
Accrued liabilities	1,266	1,169
Secured Convertible Notes, net of discounts	973	1,137
Unsecured Convertible Notes, net of discounts	34	0
Embedded derivative liability	159	0
Operating lease liability	375	368
Current liabilities, discontinued operations	0	698
Total current liabilities	3,924	4,278
Warrant liabilities	232	334
Operating lease liabilities-non-current	1,041	1,108
Total liabilities	5,197	5,720
Commitments and contingencies (Note 8)
Stockholders’ equity:
Common stock, $0.01 par value; 150,000 shares authorized, 32,025 and 11,230 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	320	112
Additional paid-in capital	176,798	176,101
Accumulated deficit	(178,443)	(174,849)
Total stockholders’ equity	160	3,314
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	5,357	9,034
Series B Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	44	275
Series C Preferred Stock [Member]
Stockholders’ equity:
Preferred Stock	$ 1,441	$ 1,675

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Accounts receivable, allowance for doubtful accounts	$ 3	$ 3
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 229	$ 264
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	32,025,000	11,230,000
Common stock, shares outstanding (in shares)	32,025,000	11,230,000
Series B Preferred Stock [Member]
Preferred stock, shares issued (in shares)	1,000	6,000
Preferred stock, shares outstanding (in shares)	1,000	6,000
Series C Preferred Stock [Member]
Preferred stock, shares issued (in shares)	1,000	1,000
Preferred stock, shares outstanding (in shares)	1,000	1,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Sales:
Total sales, net	$ 2,631	$ 2,339
Cost of goods sold	837	739
Gross profit	1,794	1,600
Operating expenses
Research and development	19	10
Sales and marketing	1,055	1,236
General and administrative	2,291	1,699
Loss on divestiture of subsidiary	865	0
Total operating expenses	4,230	2,945
Operating loss	(2,436)	(1,345)
Non-cash gain on changes in fair value of warrant liabilities	194	0
Non-cash gain on change in fair value of embedded derivative liability	65	0
Accretion of interest and amortization of discounts on convertible notes	(433)	0
Other expense, net	(480)	0
Net loss from continuing operations	(3,090)	(1,345)
Net loss from discontinued operations (Note 17)	(124)	(394)
Net loss	(3,214)	(1,739)
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price	380	0
Net loss attributable to common stockholders	$ (3,594)	$ (1,739)
Basic and diluted net loss per share
Net loss per share from continuing operations (in dollars per share)	$ (0.14)	$ (0.66)
Net loss per share from discontinued operations (in dollars per share)	(0.01)	(0.19)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.15)	$ (0.85)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares)	24,672	2,035
Product [Member]
Sales:
Total sales, net	$ 2,624	$ 2,332
Product and Service, Other [Member]
Sales:
Total sales, net	$ 7	$ 7

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Conversion of Series B Preferred Stock to Common Stock [Member] Preferred Stock [Member]	Conversion of Series B Preferred Stock to Common Stock [Member] Common Stock [Member]	Conversion of Series B Preferred Stock to Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series B Preferred Stock to Common Stock [Member] Retained Earnings [Member]	Conversion of Series B Preferred Stock to Common Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member] Preferred Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member] Common Stock [Member]	Conversion of Series C Preferred Stock to Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Series C Preferred Stock to Common Stock [Member] Retained Earnings [Member]	Conversion of Series C Preferred Stock to Common Stock [Member]	Employees and Directors [Member] Preferred Stock [Member]	Employees and Directors [Member] Common Stock [Member]	Employees and Directors [Member] Additional Paid-in Capital [Member]	Employees and Directors [Member] Retained Earnings [Member]	Employees and Directors [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022																14	2,035
Balance at Dec. 31, 2022																$ 2,973	$ 20	$ 165,713	$ (158,152)	$ 10,554
Net loss																$ 0	$ 0	0	(1,739)	(1,739)
Conversion of Preferred Stock to common stock																				0
Stock-based compensation expense related to employee and director stock awards											$ 0	$ 0	$ 75	$ 0	$ 75
Balance (in shares) at Mar. 31, 2023																14	2,035
Balance at Mar. 31, 2023																$ 2,973	$ 20	165,788	(159,891)	8,890
Balance (in shares) at Dec. 31, 2023																7	11,230
Balance at Dec. 31, 2023																$ 1,950	$ 112	176,101	(174,849)	3,314
Net loss																0	0	0	(3,214)	(3,214)
Conversion of Preferred Stock to common stock (in shares)	(5)	18,813				0	1,982
Conversion of Preferred Stock to common stock	$ (231)	$ 188	$ 43	$ 0	$ 0	$ (234)	$ 20	$ 214	$ 0	$ 0										465
Adjustment of Series C Preferred Stock conversion price																$ 0	$ 0	380	(380)	0
Stock-based compensation expense related to employee and director stock awards											$ 0	$ 0	$ 60	$ 0	$ 60
Balance (in shares) at Mar. 31, 2024																2	32,025
Balance at Mar. 31, 2024																$ 1,485	$ 320	$ 176,798	$ (178,443)	$ 160

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating activities:
Net loss	$ (3,214,000)	$ (1,739,000)
Net loss from discontinued operations	124,000	394,000
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	12,000	13,000
Stock-based compensation expense related to employee and director stock awards	60,000	75,000
Loss on divestiture of subsidiary	865,000	0
Non-cash expense incurred to obtain consent of Secured Convertible Note holders	368,000	0
Non-cash gain on changes in fair value of warrant liabilities	(194,000)	0
Non-cash gain on changes in fair value of embedded derivative liability	(65,000)	0
Accretion of interest and amortization of debt discounts on convertible notes	415,000	0
Changes in operating assets and liabilities:
Accounts receivable	(54,000)	250,000
Inventory	(107,000)	(80,000)
Prepaid expenses and other current assets	(115,000)	(45,000)
Operating lease right-of-use assets	84,000	59,000
Other assets	1,000	(6,000)
Accounts payable and accrued liabilities	308,000	(74,000)
Operating lease liabilities	(60,000)	(34,000)
Net cash used in operating activities, continuing operations	(1,572,000)	(1,187,000)
Investing activities:
Proceeds from divestiture of subsidiary	1,070,000	0
Purchases of property and equipment	(2,000)	(13,000)
Net cash provided by (used in) investing activities, continuing operations	1,068,000	(13,000)
Financing activities:
Payments on Secured Convertible Notes	(578,000)	0
Debt issuance cost	(19,000)	0
Net cash used in financing activities, continuing operations	(597,000)	0
Net decrease in cash, cash equivalents, and restricted cash, continuing operations	(1,101,000)	(1,200,000)
Net decrease in cash and cash equivalents, discontinued operations	(206,000)	(424,000)
Net decrease in cash, cash equivalents, and restricted cash, consolidated	(1,307,000)	(1,624,000)
Cash, cash equivalents and restricted cash, beginning of year, consolidated	3,606	5,846
Less: Cash and cash equivalents of discontinued operations, end of period	0	(52)
Cash, cash equivalents and restricted cash of continuing operations, end of period	2,299,000	4,170,000
Supplemental disclosure of cash flow information:
Interest paid in continuing operations	236,000	0
Interest paid in discontinued operations	0	5,000
Supplemental disclosure of non-cash information:
Conversion of Preferred Stock to common stock	465,000	0
Down round feature adjustments related to Preferred Stock	380,000	0
Issuance of embedded derivative liability in conjunction with Unsecured Convertible Notes	$ 224,000	$ 0

Note 1 - Organization

Note 1 - Organization	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1. ORGANIZATION NovaBay Pharmaceuticals, Inc. (“ our we us Company We also manufacture and sell our proprietary form of hypochlorous acid for the wound care market through our NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for the cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers and other injuries. The Company currently sells these products through distributors. Through our former subsidiary DERMAdoctor, LLC (“ DERMAdoctor 30 March 25, 2024, DERMAdoctor Divestiture The Company operated in principally two reportable segments: ( 1 2 March 25, 2024, The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, Reincorporation Discontinued Operations On March 25, 2024, March 31, 2024, In connection with the DERMAdoctor Divestiture, the Company has entered into Transition Services Agreement with New Age Investments, LLC to provide for a customary and orderly transition of the business, including warehousing services provided by New Age Investments, LLC and fulfillment services provided by the Company, which shall be included in continuing operations in subsequent periods. Going Concern The Company has sustained operating losses for the majority of its corporate history and expects that its 2024 2024 twelve may may The Company’s long-term liquidity needs will be largely determined by the success of our commercialization efforts. To address the Company’s current liquidity and capital needs, the Company has and continues to evaluate different plans and strategic transactions to fund operations, including: ( 1 2 one 3 4 5 may may 1 3 2023 2023 9, no not may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC, as of and for the three March 31, 2024. March 25, 2024, three March 31, 2024, Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these financial statements to properly report amounts under current operations and discontinued operations (see Note 17, Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may not These estimates are based on management’s best estimates and judgment. Actual results may Unaudited Condensed Consolidated Interim Financial Information The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not not The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, 10 December 31, 2023, March 26, 2024 March 29, 2024 ( “2023 Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2024 December 31, 2023, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): March 31, December 31, 2024 2023 Cash and cash equivalents $ 1,823 $ 3,130 Cash and cash equivalents, discontinued operations — (206 ) Restricted cash included in other assets 476 476 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 2,299 $ 3,400 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. During the three March 31, 2024 2023, Three Months Ended March 31, 2024 2023 Avenova Spray $ 2,096 $ 1,937 Other products 528 395 Total product revenue, net 2,624 2,332 Other revenue, net 7 7 Total sales, net $ 2,631 $ 2,339 During the three March 31, 2024 2023, three March 31, 2024 2023, As of March 31, 2024 December 31, 2023, 10% March 31, December 31, Major distribution partner 2024 2023 Major U.S. Retailer A 38 % 22 % Avenova Spray Pharmacy Distributor A 18 % 14 % Phase One Health 16 % * % Chongqing Pioneer Pharma Holdings Limited * % 36 % * Less than 10% The Company relies on one contract manufacturer to produce its products. The Company does not third may may not may Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ ASC 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. See additional information in Note 3, Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of March 31, 2024 December 31, 2023. Inventory Inventory is comprised of ( 1 2 3 first first March 31, 2024 December 31, 2023, Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred. Business Combinations, Goodwill and Indefinite-Lived Intangible Assets We account for 805, Business Combinations Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not Goodwill is evaluated for impairment by first may not Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company’s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. The Company did not three March 31, 2024 2023. Valuation of Contingent Consideration Resulting from a Business Combination In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 2023 not March 31, 2024 December 31, 2023. Long-Lived Assets The Company’s intangible assets that do not 360, Property, Plant and Equipment may may not no not The Company did not three March 31, 2024 2023. Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not not The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. Common Stock Warrants The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 815 The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black-Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See Note 3, 11, Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black-Scholes option pricing model. See Note 3, Preferred Stock Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, March 31, 2024. 820, 1 2 3, Revenue Recognition The Company’s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Revenue generated from end consumers through third third Revenue generated through major pharmacy distributors is recognized on a “sell-in” basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for product supply is typically due 30 days after delivery to the distributor. Revenue generated from end consumers through the Company’s partner pharmacies is recognized on a “sell-through” basis when control of the goods is transferred to the consumer. Revenue generated from other retailers is recognized on a “sell-through” basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third The Company defers recognition for pre-payments until the Company’s performance obligations are satisfied. Cost of Goods Sold Cost of goods sold includes third third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities. Patent Costs Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations. Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.2 million and $0.3 million, respectively, for the three March 31, 2024 2023, Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“ RSUs 13, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“ EPS Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. For the three March 31, 2024 2023, not The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Balance at March 31, 2024 2023 Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 3,616,000 1,847,580 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock 5,192,961 357,750 Stock options 116,700 121,203 Stock warrants 8,382,447 2,305,519 17,308,108 4,632,052 Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, 2023

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The following table presents the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2024 December 31, 2023 ( Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable March Items Inputs Inputs 31, 2024 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liabilities $ 232 $ — $ 232 $ — Embedded derivative liability 159 — 159 — Total liabilities $ 391 $ — $ 391 $ — Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liabilities $ 334 $ — $ 334 $ — The Company’s cash equivalents and restricted cash held as certificates of deposit are classified within Level 1 The Secured Convertible Notes (see Note 10, 2 2023 May 2023 2023 2023 3. The Unsecured Convertible Notes (see Note 10, 2 The fair value of the December 2023 2023 2023 2. See Note 11, 2 three March 31, 2024 2023. There were no 1, 2 3 three March 31, 2024 2023. Black Scholes Valuation Models and Assumptions The Company utilizes a Black Scholes model for various valuations as outlined throughout this report. The following tables summarize the assumptions utilized for valuations impacting results for the periods reported. See also Note 13, Warrant Liabilities Various of the Company’s warrants have been, or are, subject to stockholder approval upon issuance or amendment and prior to exercise. Currently, the Company’s December 2023 March 2024 11, May 2023 Warrants May 2023 Warrants December 2023 Warrants December 2023 Warrants Measurement event Issuance Stockholder Approval Issuance Reporting Date Date May 1, 2023 June 9, 2023 December 21, 2023 December 21, 2023 Total Value 1.6 million $1.4 million $0.4 million $0.3 million Gain not applicable $0.2 million not applicable $56 thousand Assumptions: Exercise price 1.30 $ 1.30 $ 0.25 $ 0.25 Market price $ 0.72 (a) $ 0.68 $ 0.23 $ 0.20 Volatility 80.1 % 77.6 % 79.3 % 79.3 % Risk-free rate 3.60 - 4.04 % 3.92 - 4.59 % 3.88 % 3.85 % Dividend yield 0.0 % 0 % 0 % 0 % Term (years) 2.1 - 5.1 % 2.0 - 5.0 5.5 5.5 December March March 2023 2024 2024 Warrants Warrant Warrant Measurement event Reporting Date Issuance Reporting Date Date March 31, 2024 March 25, 2024 March 31, 2024 Total Value $0.2 million $0.1 million $0.1 million Gain $173 thousand not applicable $21 thousand Assumptions: Exercise price $ 0.25 $ 0.14 $ 0.14 Market price $ 0.10 $ 0.13 $ 0.10 Volatility 92.3 % 86.9 % 86.9 % Risk-free rate 4.21 % 4.24 % 4.21 % Dividend yield 0 % 0 % 0 % Term (years) 5.2 5.5 5.5 (a) Adjusted for the dilutive effect of the 2023 Warrant Modifications Amendments to warrant terms are recorded as a non-cash gain (or loss) on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black-Scholes option pricing model. Fair value was determined using a Black Scholes model as outlined below. July 2020, November 2021, September 2022 & November 2022 Warrants Measurement event Prior to amendment After amendment Date April 27, 2023 April 27, 2023 Total Value $0.3 million $0.5 million Loss not applicable $0.2 million Assumptions: Exercise price $ 6.30 $ 1.50 Market price $ 0.72 (a) $ 0.72 (a) Volatility 80.1 % 80.1 % Risk-free rate 3.59 - 4.73 % 3.59 - 4.73 % Dividend yield 0.0 % 0.0 % Term (years) 1.1 - 5.6 1.1 - 5.6 May 2023 Warrants Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total Value $56 thousand $0.2 million Loss not applicable $0.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 3.92 - 4.62 % 3.92 - 4.62 % Dividend yield 0.0 % 0.0 % Term (years) 1.5 - 4.5 1.5 - 4.5 (a) Adjusted for the dilutive effect of the 2023 Preferred Stock Conversion Price Adjustments Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (see Note 12, March 31, 2024. 820, 1 2 Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date April 27, 2023 April 27, 2023 Total value (b) $9.6 million $11.6 million Deemed dividend not applicable $2.0 million Assumptions: Exercise price $ 6.30 $ 1.30 Market price $ 0.72 (a) $ 0.72 (a) Volatility 80.1 % 80.1 % Risk-free rate 4.91 % 4.91 % Dividend yield 0.0 % 0.0 % Term (in years) 0.8 0.8 Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date December 21, 2023 December 21, 2023 Total value (b) $1.7 million $6.8 million Deemed dividend not applicable $5.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 5.43 % 5.43 % Dividend yield 0.0 % 0.0 % Term (years) 0.3 0.3 Series C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date March 24, 2024 March 24, 2024 Total value (b) $0.5 million $0.9 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 0.25 $ 0.14 Market price $ 0.13 $ 0.13 Volatility 79.9 % 79.9 % Risk-free rate 5.51 % 5.51 % Dividend yield 0.0 % 0.0 % Term (in years) 0.1 0.1 (a) Adjusted for the dilutive effect of the 2023 (b) Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence. Bifurcatable Derivatives Upon issuance in March 2024, 10, Unsecured Convertible Notes derivative Unsecured Convertible Notes derivative Measurement event Issuance Reporting Date Date March 25, 2024 March 31, 2024 Total value $0.2 million $0.2 million Gain not applicable $65 thousand Assumptions: Exercise price $ 0.14 $ 0.14 Market price $ 0.13 $ 0.10 Volatility 86.9 % 86.9 % Risk-free rate 4.54 % 4.59 % Dividend yield 0.0 % 0.0 % Term (years) 2.0 2.0 Upon issuance in May 2023, 10, Secured Convertible Notes derivative Secured Convertible Notes derivative Measurement event Issuance Shareholder approval Date April 27, 2023 June 9, 2023 Total value (b) $0.2 million $0.2 million Gain not applicable $40 thousand Assumptions: Exercise price $ 1.30 $ 1.30 Market price $ 0.72 (a) $ 0.75 Volatility 80.1 % 76.9 % Risk-free rate 4.88 % 5.41 % Dividend yield 0.0 % 0.0 % Term (years) 0.8 0.7 (a) Adjusted for the dilutive effect of the 2023 (b) Adjusted for probability of occurrence.

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following (in thousands): March 31, December 31, 2024 2023 Prepaid dues and subscriptions $ 89 $ 85 Prepaid taxes 68 83 Prepaid inventory 4 73 Prepaid insurance 114 66 Other 96 81 Prepaid expenses from discontinued operations — (132 ) Total prepaid expenses and other current assets $ 371 $ 256

Note 5 - Inventory

Note 5 - Inventory	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following (in thousands): March 31, December 31, 2024 2023 Raw materials and supplies $ 160 $ 1,027 Finished goods 732 2,477 Less: Reserve for excess and obsolete inventory (229 ) (627 ) Inventory, net of reserves, from discontinued operations — (2,313 ) Total inventory, net $ 663 $ 564

Note 6 - Property and Equipment

Note 6 - Property and Equipment	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following (in thousands): March 31, December 31, 2024 2023 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 433 431 Leasehold improvements 152 152 Total property and equipment, at cost 762 760 Less: accumulated depreciation (685 ) (673 ) Total property and equipment, net $ 77 $ 87 Depreciation expense related to continuing operations was $12 thousand and $13 thousand for the three March 31, 2024 2023, three March 31, 2024 2023, March 31, 2024 December 31, 2023

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. Accrued liabilities consisted of the following (in thousands): March 31, December 31, 2024 2023 Contract liabilities (see Note 14) $ 745 $ 946 Employee payroll and benefits 308 341 Other 213 229 Accrued liabilities from discontinued operations — (347 ) Total accrued liabilities $ 1,266 $ 1,169

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8. Indemnification Agreements As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not March 31, 2024 December 31, 2023. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its clinical research organizations, investigators, clinical sites, suppliers, and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not March 31, 2024 December 31, 2023. Legal Matters From time to time, the Company is subject to various legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. The ultimate outcome of any litigation or other legal dispute is uncertain. When a loss related to a legal proceeding or claim is probable and reasonably estimable, the Company accrues its best estimate for the ultimate resolution of the matter. If one may March 31, 2024 December 31, 2023, no may not Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The current lease term expires on July 31, 2027. Lease costs for the three March 31, 2024 2023 For the Three Months Ended 2024 2023 Operating lease – expense $ 100 $ 100 Operating lease from discontinued operations – expense — 30 Operating lease – included in operating cash flow 76 74 Operating lease from discontinued operations – included in operating cash flow — 32 The Company has measured its operating lease liabilities as the present value of minimum lease payments using its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate for operating leases from continuing operations are summarized as follows: For the Three Months Ended 2024 2023 Weighted-average remaining lease term (in years) 3.3 4.0 Weighted-average discount rate 5 % 5 % Future lease payments under non-cancelable leases as of March 31, 2024 2024 $ 350 2025 439 2026 444 2027 290 Total future minimum lease payments 1,523 Less: Imputed interest (107 ) Total $ 1,416 Reported as: Operating lease liability $ 375 Operating lease liability- non-current 1,041 Total $ 1,416

Note 9 - Financing Activities

Note 9 - Financing Activities	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 9. See Notes 2, Summary of Significant Accounting Policies ; 3, Fair Value Measurements ; 10, Convertible Notes ; 11, Common Stock Warrants and 12, Stockholders Equity for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. 2024 On March 24, 2024, First Amendment April 27, 2023 ( Security Agreement Subsidiary Guarantee Consent April 7, 2023 ( Subsidiary Guarantee 2024 March 2024 11, 10 The Company issued, based on the secured parties’ elections, (i) a March 2024 four The Company incurred total issuance costs of $130 thousand in conjunction with the 2024 three March 31, 2024. 2023 In December 2023, 2023 May 2023 May 2023 2023 December 2023 The 2023 December 2023 December 2023 March 31, 2024. The Company incurred total issuance costs of $0.2 million in conjunction with the 2023 2023 In May 2023, 2023 May 2023 The Company received gross proceeds of $3.0 million from the 2023 2023 May 2023 first May 2023 The Company incurred total issuance costs of $0.7 million in conjunction with the 2023

Note 10 - Convertible Notes

Note 10 - Convertible Notes	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 10. Unsecured Convertible Note In March 2024, Unsecured Convertible Notes 2024 2024 9, 17, March 25, 2026 no The Unsecured Convertible Notes may not September 25, 2024, Upon issuance in March 2024, 3, no March 31, 2024. March 31, 2024 3, The discount to the note recorded for the embedded derivative liability upon issuance and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Unsecured Convertible Notes, assuming that the Unsecured Convertible Notes will be redeemed for cash of $525 thousand at time of maturity as of March 25, 2026. three March 31, 2024, three March 31, 2024, Secured Convertible Note In May 2023, Secured Convertible Notes 2023 9, November 1, 2024. The Secured Convertible Notes may March 31, 2024, Beginning June 1, 2023, 1/18 th may not March 31, 2024 The Secured Convertible Notes also provide for a redemption equal to up to 20% of the gross proceeds received by the Company from any financing completed while the Secured Convertible Notes are outstanding. In connection with the 2023 12, If any event of default occurs, the outstanding principal amount of the Secured Convertible Notes, plus accrued but unpaid interest, liquidated damages and other amounts owing thereof become immediately due and payable in cash at the holder’s election. After any event of default, the Secured Convertible Notes will also accrue interest at a rate up to 18% per year. The Secured Convertible Notes are secured obligations of the Company including a security interest, a lien upon and a right of set-off against all of the Company’s assets as collateral security. DERMAdoctor was released of such obligations in connection with the DERMAdoctor Divestiture. Upon issuance in May 2023, no 3, The lender’s subsequent financing redemption option and certain events of default also represent embedded call options and the Company’s monthly share redemption option represents an embedded put option. The fair value of these options was determined to be immaterial upon issuance and at each subsequent reporting date. The Company allocated $1.2 million of gross proceeds from the 2023 The difference between the $1.2 million allocated to the Secured Convertible Notes and the $3.3 million aggregate principal amount represent discounts for the portion of proceeds allocated to the embedded derivative liability and the May 2023 11, The discounts and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Secured Convertible Notes, assuming that the Secured Convertible Notes will be redeemed for cash of $193 thousand per month beginning in June 2023. three March 31, 2024, The Secured Convertible Notes are presented as follows as of March 31, 2024 ( Principal amount $ 1,314 Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants (293 ) Unamortized debt issuance costs (48 ) Total Secured Convertible Notes, net $ 973 The Secured Convertible Notes, net, are classified as short term in the Company’s condensed consolidated balance sheets. As of March 31, 2024, 2024 $ 1,314

Note 11 - Common Stock Warrants

Note 11 - Common Stock Warrants	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Stockholders' Equity Note, Warrants or Rights Disclosure [Text Block]	NOTE 11. See Notes 2, Summary of Significant Accounting Policies ; 3, Fair Value Measurements ; 9, Financing Activities ; and 12, Stockholders Equity for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates. March 2024 In March 2024, 2024 10, 9, 17, March 2024 17, March2024 Upon issuance, the March 2024 not March 31, 2024. December 2023 In December 2023, 2023 December 2023 June 21, 2029. December 2023 not March 31, 2024. May 2023 In May 2023, 2023 May 2023 ● May 2023 1 June 9, 2028 (“ May 2023 1 ● May 2023 2 June 9, 2025 (“ May 2023 2 In December 2023, 2023 May 2023 May 2023 May 2023 ● May 2023 1 ● May 2023 2 For the amendment in December 2023, May 2023 November 2022 In November 2022, 2022 November 2022 ● November 2022 1 November 20, 2024 (“ November 2022 1 ● November 2022 2 May 20, 2024 (“ November 2022 2 In May 2023, 2023 November 2022 ● November 2022 1 ● November 2022 2 For the amendment in May 2023, November 2022 September 2022 In September 2022, 2022 September 2022 September 11, 2028. In May 2023, 2023 September 2022 For the amendment in May 2023, September 2022 November 2021 In November 2021, November 2021 March 9, 2023. In September 2022, 2022 November 2021 September 11, 2028. November 2021 In May 2023, 2023 November 2021 For the amendments in September 2022 May 2023, November 2021 July 2020 In July 2020, July 2020 ) January 22, 2026. In September 2022, 2022 July 2020 July 2020 In May 2023, 2023 July 2020 For the amendments in September 2022 May 2023, July 2020 Summary of Common Stock Warrant Activity and Outstanding Activity related to common stock warrants outstanding during the three March 31, 2024 2023 Warrants Weighted- Average Exercise Price Outstanding at December 31, 2022 2,305,519 $ 7.70 Warrants granted — — Warrants exercised — — Warrants expired — — Outstanding at March 31, 2023 2,305,519 7.70 Outstanding at December 31, 2023 7,382,447 $ 1.82 Warrants granted 1,000,000 0.14 Warrants exercised — — Warrants expired — — Outstanding at March 31, 2024 8,382,447 1.60 Common stock warrants outstanding as of March 31, 2024 Series Exercise Price Expiration Date Warrants 2019 Ladenburg Warrants $ 34.65 August 8, 2024 4,799 July 2020 Warrants $ 57.75 January 22, 2026 59,960 July 2020 Warrants $ 1.50 January 22, 2026 77,145 TLF Warrants $ 23.51 January 15, 2026 429 November 2021 Warrants $ 6.30 September 11, 2028 267,858 November 2021 Warrants $ 1.50 September 11, 2028 535,716 September 2022 Warrants $ 6.30 September 11, 2028 89,286 September 2022 Warrants $ 1.50 September 11, 2028 238,574 November 2022 A-1 Warrants $ 6.30 November 20, 2028 79,366 November 2022 A-1 Warrants $ 1.50 November 20, 2028 436,510 November 2022 A-2 Warrants $ 6.30 May 20, 2024 79,366 November 2022 A-2 Warrants $ 1.50 May 20, 2024 436,510 May 2023 B-1 Warrants $ 1.30 June 9, 2028 1,903,848 May 2023 B-2 Warrants $ 1.30 June 9, 2025 644,232 December 2023 Warrants $ 0.25 June 21, 2029 2,528,848 March 2024 Warrant $ 0.14 To be determined (*) 1,000,000 Outstanding at March 31, 2024 8,382,447 *The March 2024 six March 2024 five March 2024 Summary of Common Stock Warrant Liabilities The following is a reconciliation of the beginning and ending balances for warrant liabilities measured at fair value on a recurring basis (in thousands). See additional information per Note 3, Warrant liabilities as of December 31, 2023 334 Decrease in fair value of December 2023 Warrants liability during period (173 ) Fair value of March 2024 Warrant upon issuance 92 Decrease in fair value of March 2024 Warrant liability after issuance (21 ) Warrant liabilities as of March 31, 2024 $ 232

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Equity [Text Block]	NOTE 12. EQUITY Authorized Share Capital Under the Company’s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to 150,000,000 shares of common stock and up to 5,000,000 shares of preferred stock with rights and preferences as may Preferred Stock There were two three March 31, 2024 2023 Series B Preferred Stock Series C Preferred Stock Preferred Stock not Ratchet Series B Preferred Stock The Company issued 15,000 shares of Series B Preferred Stock in November 2021 March 31, 2024 2023, March 31, 2024 2023, In accordance with the Ratchet, the Series B Preferred Stock conversion price was reduced as follows (see also Notes 2, 3, ● In September 2022, 2022 ● In April 2023, 2023 ● In December 2023, 2023 On January 29, 2024, no Series C Preferred Stock We issued 3,250 shares of Series C Preferred Stock in November 2022 2022 9, March 31, 2024 2023, March 31, 2024 2023, $6.30, In accordance with the Ratchet, the Series C Preferred Stock conversion price was reduced as follows during the three March 31, 2024 2023 2, 3, ● In April 2023, 2023 ● In December 2023, 2023 ● In March 2024, 2024 On March 27, 2024, no Common Stock See Note 9, 11, three March 31, 2024 2023.

Note 13 - Equity-based Compensa

Note 13 - Equity-based Compensation	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 13. Equity Compensation Plans In October 2007, 2007 2007 2007 March 15, 2017. 2007 2007 no ten 2007 December 31, 2021. In March 2017, 2017 2017 Plan June 2, 2017, NQSOs ISOs SARs 2017 not 2007 2017 first January 1, 2018 January 1, 2027 March 31, 2023, 2017 March 31, 2024, 2017 Under the terms of the 2017 may not not not ten no five 10% four 2007 2017 Summary of Outstanding Equity Awards The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2023, three March 31, 2024: (in thousands, except years and per share data) Awards Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2023 125 $ 31.15 7.3 $ 1 Options forfeited/cancelled (8 ) $ 20.36 Outstanding at March 31, 2024 117 $ 31.91 6.8 $ 1 Vested and expected to vest at March 31, 2024 111 $ 33.17 6.7 $ 1 Vested and exercisable at March 31, 2024 62 $ 56.86 5.0 $ — The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of March 31, 2024 three March 31, 2024 2023. three March 31, 2024 2023. As of March 31, 2024, Equity Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the three March 31, 2024, not three March 31, 2023, The weighted-average assumptions used in determining the value of options were as follows: Assumption For the Three Months Ended March 31, 2023 Expected price volatility 154.49 % Expected term (in years) 6.66 Risk-free interest rate 3.41 % Dividend yield 0.00 % Weighted-average fair value of options granted during the period $ 2.37 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. During the three March 31, 2024 2023, not For the three March 31, 2024 2023, Stock-Based Awards to Non-Employees During the three March 31, 2024 2023, not The Company did not three March 31, 2024. For the three March 31, 2024 2023, Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows (in thousands): For the Three Months Ended March 31, 2024 2023 Research and development $ 4 $ 6 Sales and marketing 26 15 General and administrative 30 54 Total stock-based compensation expense $ 60 $ 75

Note 14 - Distribution Agreemen

Note 14 - Distribution Agreements	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
License, Collaboration, and Distribution Agreements [Text Block]	NOTE 14. Transactions under the Company’s major distribution agreements are recognized upon transfer of control of products sold to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the amounts that are estimated to be subject to significant reversal, including allowances for services, discounts, rebate programs, and product returns. Product Sales Discounts and Allowances The following table presents activities and ending reserve balances for each significant category of discounts and allowance, which constitute variable consideration, for the three March 31, 2024 ( Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2023 $ 913 $ 12 $ 21 $ 946 Less discontinued operations (218 ) — — (218 ) Continuing operations balance at December 31, 2023 695 12 21 728 Provision related to sales made in: Current period 26 8 18 52 Payments and customer credits issued (2 ) (7 ) (26 ) (35 ) Balance at March 31, 2024 $ 719 $ 13 $ 13 $ 745 Avenova Spray Pharmacy Distribution Agreements and Specialty Pharmacies Avenova Spray is made available in local pharmacies and major pharmacy retail chains under nationwide distribution agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen. The Company has also entered into direct agreements with preferred pharmacy networks as part of our Partner Pharmacy Program. During the three March 31, 2024 2023, Under these product distribution arrangements, the Company had a contract liability balance of $0.7 million as of March 31, 2024 December 31, 2023. Over-the-Counter Sales of Avenova Spray Avenova Spray is offered for sale direct to U.S. customers primarily on Amazon.com, the Company’s website (Avenova.com) and Walmart.com. During the three March 31, 2024 2023,

Note 15 - Employee Benefit Plan

Note 15 - Employee Benefit Plan	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 15. The Company has a 401 first three March 31, 2024 2023, three March 31, 2023.

Note 16 - Segment Reporting

Note 16 - Segment Reporting	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 16. The Company operates as one reportable segment, Eyecare and Wound Care, which is described in further detail below. This is based on the objectives of the business and how our chief operating decision maker (CODM), the President and Chief Executive Officer, monitors operating performance and allocates resources. Change in Reportable Segments The Company previously operated in principally two reportable segments, ( 1 2 three March 31, 2024, We now manage and report our operating results through one reportable segment: Eyecare and Wound Care. This change allows us to better align our business models, resources, and cost structure to the specific current and future growth of our business, while maintaining the necessary information and transparency to our stockholders. Our historical segment information has been recast to conform to the current segment structure.

Note 17 - Divestiture and Disco

Note 17 - Divestiture and Discontinued Operations	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	NOTE 17. On March 12, 2024, March 25, 2024. 10, May 2023 On March 24, 2024, March 2024 10 The accounting requirements for reporting the DERMAdoctor business as discontinued operations were met during the first 2024. In accordance with the provisions of ASC 205 20, December 31, 2023, Balance at December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 206 Accounts receivable, net of allowance for credit losses ($ 0 79 Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($ 363 2,313 Prepaid expenses and other current assets 132 Total current assets, discontinued operations 2,730 Other assets 19 Total assets, discontinued operations $ 2,749 LIABILITIES Liabilities: Current liabilities: Accounts payable $ 224 Accrued liabilities 347 Operating lease liabilities 127 Total current liabilities, discontinued operations 698 Total liabilities, discontinued operations $ 698 In accordance with the provisions of ASC 205 20, not three March 31, 2024 2023 Three Months Ended March 31, 2024 2023 Sales: Product revenue, net $ 717 $ 785 Total sales, net 717 785 Cost of goods sold 493 449 Gross profit 224 336 Operating expenses Research and development 2 16 Sales and marketing 292 417 General and administrative 48 292 Total operating expenses 342 725 Operating loss (118 ) (389 ) Other expense, net (6 ) (5 ) Net loss from discontinued operations $ (124 ) $ (394 ) In accordance with the provisions of ASC 205 20, not three March 31, 2024 2023 Three Months Ended March 31, 2024 2023 Operating activities: Net loss from discontinued operations $ (124 ) $ (394 ) Adjustments to reconcile net loss to net cash used in operating activities: Amortization of intangible assets — 38 Changes in operating assets and liabilities: Accounts receivable (262 ) (112 ) Inventory 183 (280 ) Prepaid expenses and other current assets (4 ) 89 Operating lease right-of-use assets — 28 Other assets 15 9 Accounts payable and accrued liabilities 63 227 Operating lease liabilities (31 ) (29 ) Net cash used in operating activities, discontinued operations (160 ) (424 ) Investing activities: Cash transferred to New Age Investments, LLC (46 ) — Net cash used in investing activities, discontinued operations (46 ) — Net decrease in cash and cash equivalents, discontinued operations $ (206 ) $ (424 )

Note 18 - Subsequent Events

Note 18 - Subsequent Events	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 18. The Company has evaluated all subsequent events through the filing date of this Form 10 March 31, 2024 , not no On April 18, 2024, NYSE American not 1003 1003 $4.0 three four $6.0 five 1009 May 18, 2024 1003 1003 October 18, 2025. Subsequent to the three March 31, 2024,

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	ITEM 5. OTHER INFORMATION During the three March 31, 2024, none 16 10b5 1 10b5 1 408
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of NovaBay Pharmaceuticals, Inc. and its former wholly-owned subsidiary, DERMAdoctor, LLC, as of and for the three March 31, 2024. March 25, 2024, three March 31, 2024,
Reclassification, Comparability Adjustment [Policy Text Block]	Financial Statement Reclassification Certain account balances from prior periods have been reclassified in these condensed consolidated financial statements to conform to current period classifications. The prior year amounts have been modified in these financial statements to properly report amounts under current operations and discontinued operations (see Note 17,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results may not These estimates are based on management’s best estimates and judgment. Actual results may
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Information The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation. The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not not The condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2023, 10 December 31, 2023, March 26, 2024 March 29, 2024 ( “2023
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three March 31, 2024 December 31, 2023, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands): March 31, December 31, 2024 2023 Cash and cash equivalents $ 1,823 $ 3,130 Cash and cash equivalents, discontinued operations — (206 ) Restricted cash included in other assets 476 476 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 2,299 $ 3,400 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States. The Company has a significant amount of its cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. During the three March 31, 2024 2023, Three Months Ended March 31, 2024 2023 Avenova Spray $ 2,096 $ 1,937 Other products 528 395 Total product revenue, net 2,624 2,332 Other revenue, net 7 7 Total sales, net $ 2,631 $ 2,339 During the three March 31, 2024 2023, three March 31, 2024 2023, As of March 31, 2024 December 31, 2023, 10% March 31, December 31, Major distribution partner 2024 2023 Major U.S. Retailer A 38 % 22 % Avenova Spray Pharmacy Distributor A 18 % 14 % Phase One Health 16 % * % Chongqing Pioneer Pharma Holdings Limited * % 36 % * Less than 10% The Company relies on one contract manufacturer to produce its products. The Company does not third may may not may
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company follows Accounting Standards Codification (“ ASC 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. See additional information in Note 3,
Credit Loss, Financial Instrument [Policy Text Block]	Allowance for Credit Losses The Company maintains an allowance for estimated losses resulting from the inability of its customers to meet their financial obligations to the Company. The Company recognizes an allowance for credit losses based on factors such as historical experience, contract terms and general and market business conditions. The Company’s future collection experience can differ significantly from historical collection trends due to such factors as changing customer circumstances and uncertain economic and industry trends. The allowance is re-evaluated on a regular basis and adjusted as needed. Once a receivable is deemed to be uncollectible, such balance is charged against the allowance. Management recorded a reserve for allowance for credit losses of $3 thousand as of March 31, 2024 December 31, 2023.
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 first first March 31, 2024 December 31, 2023,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three five five seven The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Business Combinations, Goodwill and Indefinite-Lived Intangible Assets We account for 805, Business Combinations Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not Goodwill is evaluated for impairment by first may not Management makes critical assumptions and estimates in completing impairment assessments of goodwill and indefinite-lived intangible assets. The Company’s cash flow projections look several years into the future and include assumptions on variables such as future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. The Company did not three March 31, 2024 2023.
Valuation of Contingent Consideration from Business Combination Policy [Policy Text Block]	Valuation of Contingent Consideration Resulting from a Business Combination In connection with the DERMAdoctor acquisition, the Company was subject to paying consideration that was contingent upon the achievement of specified milestone events. The Company recorded this contingent consideration at its fair value on the acquisition date. Each quarter thereafter, the Company revalued the contingent consideration and recorded changes in fair value within the condensed consolidated statements of operations. The DERMAdoctor acquisition milestone events consisted of financial targets for calendar years 2022 2023 not March 31, 2024 December 31, 2023.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The Company’s intangible assets that do not 360, Property, Plant and Equipment may may not no not The Company did not three March 31, 2024 2023.
Lessee, Leases [Policy Text Block]	Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not not The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
Warrant Liabilities [Policy Text Block]	Common Stock Warrants The Company accounts for the issuance of common stock purchase warrants issued in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 815 The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black-Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See Note 3, 11, Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black-Scholes option pricing model. See Note 3,
Preferred Stock [Policy Text Block]	Preferred Stock Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 12, March 31, 2024. 820, 1 2 3,
Revenue [Policy Text Block]	Revenue Recognition The Company’s product revenue recognition policies are established in accordance with ASC 606, Revenue from Contracts with Customers five i. identify the contract(s) with a customer; ii. identify the performance obligations in the contract; iii. determine the transaction price; iv. allocate the transaction price to the performance obligations in the contract; and v. recognize revenue when (or as) the entity satisfies performance obligations. Revenue is recognized in accordance with the amount of consideration which the Company expects to receive. Revenue generated from end consumers through third third Revenue generated through major pharmacy distributors is recognized on a “sell-in” basis when control of the goods is transferred to the distributor, which generally occurs upon delivery of the products to the distributor. Revenue is recorded net of consideration for contract liabilities for distributor services, discounts, rebates, and product returns. The Company estimates returns and other contract liabilities based on historical data which is updated quarterly. Payment for product supply is typically due 30 days after delivery to the distributor. Revenue generated from end consumers through the Company’s partner pharmacies is recognized on a “sell-through” basis when control of the goods is transferred to the consumer. Revenue generated from other retailers is recognized on a “sell-through” basis, net of estimated future product returns, when control of the goods is transferred to the retailer, which generally occurs upon delivery of the products to a third The Company defers recognition for pre-payments until the Company’s performance obligations are satisfied.
Cost of Goods and Service [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities.
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations.
Advertising Cost [Policy Text Block]	Advertising Costs Advertising costs are expensed in the period in which the costs are incurred. Advertising costs are included in sales and marketing expenses in the condensed consolidated statements of operations. Advertising expenses were $0.2 million and $0.3 million, respectively, for the three March 31, 2024 2023,
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company’s stock-based compensation includes grants of stock options and restricted stock units (“ RSUs 13,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“ EPS Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive. For the three March 31, 2024 2023, not The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Balance at March 31, 2024 2023 Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 3,616,000 1,847,580 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock 5,192,961 357,750 Stock options 116,700 121,203 Stock warrants 8,382,447 2,305,519 17,308,108 4,632,052
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements For information regarding recent accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, 2023

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	March 31, December 31, 2024 2023 Cash and cash equivalents $ 1,823 $ 3,130 Cash and cash equivalents, discontinued operations — (206 ) Restricted cash included in other assets 476 476 Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows $ 2,299 $ 3,400
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2024 2023 Avenova Spray $ 2,096 $ 1,937 Other products 528 395 Total product revenue, net 2,624 2,332 Other revenue, net 7 7 Total sales, net $ 2,631 $ 2,339
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	March 31, December 31, Major distribution partner 2024 2023 Major U.S. Retailer A 38 % 22 % Avenova Spray Pharmacy Distributor A 18 % 14 % Phase One Health 16 % * % Chongqing Pioneer Pharma Holdings Limited * % 36 %
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Balance at March 31, 2024 2023 Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “ Series B Preferred Stock 3,616,000 1,847,580 Common stock equivalent of Series C Non-Voting Convertible Preferred Stock (the “ Series C Preferred Stock 5,192,961 357,750 Stock options 116,700 121,203 Stock warrants 8,382,447 2,305,519 17,308,108 4,632,052

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable March Items Inputs Inputs 31, 2024 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liabilities $ 232 $ — $ 232 $ — Embedded derivative liability 159 — 159 — Total liabilities $ 391 $ — $ 391 $ — Fair Value Measurements Using Quoted Prices in Active Markets Significant for Other Significant Balance at Identical Observable Unobservable December Items Inputs Inputs 31, 2023 (Level 1) (Level 2) (Level 3) Assets Restricted cash held as a certificate of deposit $ 476 $ 476 $ — $ — Liabilities Warrant liabilities $ 334 $ — $ 334 $ —
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	May 2023 Warrants May 2023 Warrants December 2023 Warrants December 2023 Warrants Measurement event Issuance Stockholder Approval Issuance Reporting Date Date May 1, 2023 June 9, 2023 December 21, 2023 December 21, 2023 Total Value 1.6 million $1.4 million $0.4 million $0.3 million Gain not applicable $0.2 million not applicable $56 thousand Assumptions: Exercise price 1.30 $ 1.30 $ 0.25 $ 0.25 Market price $ 0.72 (a) $ 0.68 $ 0.23 $ 0.20 Volatility 80.1 % 77.6 % 79.3 % 79.3 % Risk-free rate 3.60 - 4.04 % 3.92 - 4.59 % 3.88 % 3.85 % Dividend yield 0.0 % 0 % 0 % 0 % Term (years) 2.1 - 5.1 % 2.0 - 5.0 5.5 5.5 December March March 2023 2024 2024 Warrants Warrant Warrant Measurement event Reporting Date Issuance Reporting Date Date March 31, 2024 March 25, 2024 March 31, 2024 Total Value $0.2 million $0.1 million $0.1 million Gain $173 thousand not applicable $21 thousand Assumptions: Exercise price $ 0.25 $ 0.14 $ 0.14 Market price $ 0.10 $ 0.13 $ 0.10 Volatility 92.3 % 86.9 % 86.9 % Risk-free rate 4.21 % 4.24 % 4.21 % Dividend yield 0 % 0 % 0 % Term (years) 5.2 5.5 5.5 July 2020, November 2021, September 2022 & November 2022 Warrants Measurement event Prior to amendment After amendment Date April 27, 2023 April 27, 2023 Total Value $0.3 million $0.5 million Loss not applicable $0.2 million Assumptions: Exercise price $ 6.30 $ 1.50 Market price $ 0.72 (a) $ 0.72 (a) Volatility 80.1 % 80.1 % Risk-free rate 3.59 - 4.73 % 3.59 - 4.73 % Dividend yield 0.0 % 0.0 % Term (years) 1.1 - 5.6 1.1 - 5.6 May 2023 Warrants Measurement event Prior to amendment After amendment Date December 21, 2023 December 21, 2023 Total Value $56 thousand $0.2 million Loss not applicable $0.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 3.92 - 4.62 % 3.92 - 4.62 % Dividend yield 0.0 % 0.0 % Term (years) 1.5 - 4.5 1.5 - 4.5 Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date April 27, 2023 April 27, 2023 Total value (b) $9.6 million $11.6 million Deemed dividend not applicable $2.0 million Assumptions: Exercise price $ 6.30 $ 1.30 Market price $ 0.72 (a) $ 0.72 (a) Volatility 80.1 % 80.1 % Risk-free rate 4.91 % 4.91 % Dividend yield 0.0 % 0.0 % Term (in years) 0.8 0.8 Series B & C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date December 21, 2023 December 21, 2023 Total value (b) $1.7 million $6.8 million Deemed dividend not applicable $5.1 million Assumptions: Exercise price $ 1.30 $ 0.25 Market price $ 0.23 $ 0.23 Volatility 79.3 % 79.3 % Risk-free rate 5.43 % 5.43 % Dividend yield 0.0 % 0.0 % Term (years) 0.3 0.3 Series C Preferred Stock Measurement event Prior to Ratchet After Ratchet Date March 24, 2024 March 24, 2024 Total value (b) $0.5 million $0.9 million Deemed dividend not applicable $0.4 million Assumptions: Exercise price $ 0.25 $ 0.14 Market price $ 0.13 $ 0.13 Volatility 79.9 % 79.9 % Risk-free rate 5.51 % 5.51 % Dividend yield 0.0 % 0.0 % Term (in years) 0.1 0.1 Unsecured Convertible Notes derivative Unsecured Convertible Notes derivative Measurement event Issuance Reporting Date Date March 25, 2024 March 31, 2024 Total value $0.2 million $0.2 million Gain not applicable $65 thousand Assumptions: Exercise price $ 0.14 $ 0.14 Market price $ 0.13 $ 0.10 Volatility 86.9 % 86.9 % Risk-free rate 4.54 % 4.59 % Dividend yield 0.0 % 0.0 % Term (years) 2.0 2.0 Secured Convertible Notes derivative Secured Convertible Notes derivative Measurement event Issuance Shareholder approval Date April 27, 2023 June 9, 2023 Total value (b) $0.2 million $0.2 million Gain not applicable $40 thousand Assumptions: Exercise price $ 1.30 $ 1.30 Market price $ 0.72 (a) $ 0.75 Volatility 80.1 % 76.9 % Risk-free rate 4.88 % 5.41 % Dividend yield 0.0 % 0.0 % Term (years) 0.8 0.7

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, December 31, 2024 2023 Prepaid dues and subscriptions $ 89 $ 85 Prepaid taxes 68 83 Prepaid inventory 4 73 Prepaid insurance 114 66 Other 96 81 Prepaid expenses from discontinued operations — (132 ) Total prepaid expenses and other current assets $ 371 $ 256

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, 2024 2023 Raw materials and supplies $ 160 $ 1,027 Finished goods 732 2,477 Less: Reserve for excess and obsolete inventory (229 ) (627 ) Inventory, net of reserves, from discontinued operations — (2,313 ) Total inventory, net $ 663 $ 564

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, 2024 2023 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 433 431 Leasehold improvements 152 152 Total property and equipment, at cost 762 760 Less: accumulated depreciation (685 ) (673 ) Total property and equipment, net $ 77 $ 87

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2024 2023 Contract liabilities (see Note 14) $ 745 $ 946 Employee payroll and benefits 308 341 Other 213 229 Accrued liabilities from discontinued operations — (347 ) Total accrued liabilities $ 1,266 $ 1,169

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Lease, Cost [Table Text Block]	For the Three Months Ended 2024 2023 Operating lease – expense $ 100 $ 100 Operating lease from discontinued operations – expense — 30 Operating lease – included in operating cash flow 76 74 Operating lease from discontinued operations – included in operating cash flow — 32 For the Three Months Ended 2024 2023 Weighted-average remaining lease term (in years) 3.3 4.0 Weighted-average discount rate 5 % 5 %
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	2024 $ 350 2025 439 2026 444 2027 290 Total future minimum lease payments 1,523 Less: Imputed interest (107 ) Total $ 1,416 Reported as: Operating lease liability $ 375 Operating lease liability- non-current 1,041 Total $ 1,416

Note 10 - Convertible Notes (Ta

Note 10 - Convertible Notes (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Long-Term Debt Instruments [Table Text Block]	Principal amount $ 1,314 Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants (293 ) Unamortized debt issuance costs (48 ) Total Secured Convertible Notes, net $ 973
Schedule of Maturities of Long-Term Debt [Table Text Block]	2024 $ 1,314

Note 11 - Common Stock Warran_2

Note 11 - Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Weighted- Average Exercise Price Outstanding at December 31, 2022 2,305,519 $ 7.70 Warrants granted — — Warrants exercised — — Warrants expired — — Outstanding at March 31, 2023 2,305,519 7.70 Outstanding at December 31, 2023 7,382,447 $ 1.82 Warrants granted 1,000,000 0.14 Warrants exercised — — Warrants expired — — Outstanding at March 31, 2024 8,382,447 1.60
Schedule of Stockholders' Equity Note, Warrants or Rights Outstanding, Activity [Table Text Block]	Series Exercise Price Expiration Date Warrants 2019 Ladenburg Warrants $ 34.65 August 8, 2024 4,799 July 2020 Warrants $ 57.75 January 22, 2026 59,960 July 2020 Warrants $ 1.50 January 22, 2026 77,145 TLF Warrants $ 23.51 January 15, 2026 429 November 2021 Warrants $ 6.30 September 11, 2028 267,858 November 2021 Warrants $ 1.50 September 11, 2028 535,716 September 2022 Warrants $ 6.30 September 11, 2028 89,286 September 2022 Warrants $ 1.50 September 11, 2028 238,574 November 2022 A-1 Warrants $ 6.30 November 20, 2028 79,366 November 2022 A-1 Warrants $ 1.50 November 20, 2028 436,510 November 2022 A-2 Warrants $ 6.30 May 20, 2024 79,366 November 2022 A-2 Warrants $ 1.50 May 20, 2024 436,510 May 2023 B-1 Warrants $ 1.30 June 9, 2028 1,903,848 May 2023 B-2 Warrants $ 1.30 June 9, 2025 644,232 December 2023 Warrants $ 0.25 June 21, 2029 2,528,848 March 2024 Warrant $ 0.14 To be determined (*) 1,000,000 Outstanding at March 31, 2024 8,382,447
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Warrant liabilities as of December 31, 2023 334 Decrease in fair value of December 2023 Warrants liability during period (173 ) Fair value of March 2024 Warrant upon issuance 92 Decrease in fair value of March 2024 Warrant liability after issuance (21 ) Warrant liabilities as of March 31, 2024 $ 232

Note 13 - Equity-based Compen_2

Note 13 - Equity-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Awards Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2023 125 $ 31.15 7.3 $ 1 Options forfeited/cancelled (8 ) $ 20.36 Outstanding at March 31, 2024 117 $ 31.91 6.8 $ 1 Vested and expected to vest at March 31, 2024 111 $ 33.17 6.7 $ 1 Vested and exercisable at March 31, 2024 62 $ 56.86 5.0 $ —
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	For the Three Months Ended March 31, 2024 2023 Research and development $ 4 $ 6 Sales and marketing 26 15 General and administrative 30 54 Total stock-based compensation expense $ 60 $ 75
Employees and Directors [Member]
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Assumption For the Three Months Ended March 31, 2023 Expected price volatility 154.49 % Expected term (in years) 6.66 Risk-free interest rate 3.41 % Dividend yield 0.00 % Weighted-average fair value of options granted during the period $ 2.37

Note 14 - Distribution Agreem_2

Note 14 - Distribution Agreements (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Chargebacks, Discounts for Prompt Payment Other Customer Fees Rebates Total Balance at December 31, 2023 $ 913 $ 12 $ 21 $ 946 Less discontinued operations (218 ) — — (218 ) Continuing operations balance at December 31, 2023 695 12 21 728 Provision related to sales made in: Current period 26 8 18 52 Payments and customer credits issued (2 ) (7 ) (26 ) (35 ) Balance at March 31, 2024 $ 719 $ 13 $ 13 $ 745

Note 17 - Divestiture and Dis_2

Note 17 - Divestiture and Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	Balance at December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 206 Accounts receivable, net of allowance for credit losses ($ 0 79 Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($ 363 2,313 Prepaid expenses and other current assets 132 Total current assets, discontinued operations 2,730 Other assets 19 Total assets, discontinued operations $ 2,749 LIABILITIES Liabilities: Current liabilities: Accounts payable $ 224 Accrued liabilities 347 Operating lease liabilities 127 Total current liabilities, discontinued operations 698 Total liabilities, discontinued operations $ 698 Three Months Ended March 31, 2024 2023 Sales: Product revenue, net $ 717 $ 785 Total sales, net 717 785 Cost of goods sold 493 449 Gross profit 224 336 Operating expenses Research and development 2 16 Sales and marketing 292 417 General and administrative 48 292 Total operating expenses 342 725 Operating loss (118 ) (389 ) Other expense, net (6 ) (5 ) Net loss from discontinued operations $ (124 ) $ (394 ) Three Months Ended March 31, 2024 2023 Operating activities: Net loss from discontinued operations $ (124 ) $ (394 ) Adjustments to reconcile net loss to net cash used in operating activities: Amortization of intangible assets — 38 Changes in operating assets and liabilities: Accounts receivable (262 ) (112 ) Inventory 183 (280 ) Prepaid expenses and other current assets (4 ) 89 Operating lease right-of-use assets — 28 Other assets 15 9 Accounts payable and accrued liabilities 63 227 Operating lease liabilities (31 ) (29 ) Net cash used in operating activities, discontinued operations (160 ) (424 ) Investing activities: Cash transferred to New Age Investments, LLC (46 ) — Net cash used in investing activities, discontinued operations (46 ) — Net decrease in cash and cash equivalents, discontinued operations $ (206 ) $ (424 )

Note 1 - Organization (Details

Note 1 - Organization (Details Textual) $ in Thousands		3 Months Ended		12 Months Ended
	Mar. 25, 2024 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2023
Number of Reportable Segments		1		2
Proceeds from Divestiture of Businesses		$ 1,070	$ 0
Gain (Loss) on Disposition of Business		(865)	$ 0
Discontinued Operations, Disposed of by Sale [Member] | DERMAdoctor [Member]
Proceeds from Divestiture of Businesses	$ 1,100
Gain (Loss) on Disposition of Business		$ (900)

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Number of Major Source Manufacturers	1
Accounts Receivable, Allowance for Credit Loss	$ 3		$ 3
Inventory Valuation Reserves	229		264
Goodwill and Intangible Asset Impairment	0	$ 0
Business Combination, Contingent Consideration, Liability	0		$ 0
Impairment, Long-Lived Asset, Held-for-Use	$ 0	0
Payment for Product Supply Period (Day)	30 days
Advertising Expense	$ 200	$ 300
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Revenue from Contract with Customer Benchmark [Member] | Distributor Concentration Risk [Member] | Avenova Spray [Member]
Concentration Risk, Percentage	74%	75%

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Cash and cash equivalents	$ 1,823	$ 3,130
Cash and cash equivalents, discontinued operations	0	(206)
Restricted cash included in other assets	476	476
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows	$ 2,299	$ 3,400

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total sales, net	$ 2,631	$ 2,339
Avenova Spray [Member]
Total sales, net	2,096	1,937
Other Products [member]
Total sales, net	528	395
Total Product Revenue [Member]
Total sales, net	2,624	2,332
Product and Service, Other [Member]
Total sales, net	$ 7	$ 7

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Major U.S. Retailer A [Member]
Accounts receivable, concentration risk	38%	22%
Distributor B [Member]
Accounts receivable, concentration risk	18%	14%
Phase One Health, LLC [Member]
Accounts receivable, concentration risk	16%
Chongqing Pioneer Pharma Holdings Limited [Member]
Accounts receivable, concentration risk		36%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Anti-dilutive securities (in shares)	17,308,108	4,632,052
Series B Preferred Stock [Member]
Anti-dilutive securities (in shares)	3,616,000	1,847,580
Series C Preferred Stock [Member]
Anti-dilutive securities (in shares)	5,192,961	357,750
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	116,700	121,203
Warrant [Member]
Anti-dilutive securities (in shares)	8,382,447	2,305,519

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Restricted cash held as a certificate of deposit	$ 476	$ 476
Warrant liabilities	232	334
Embedded derivative liability	159
Total liabilities	391
Fair Value, Inputs, Level 1 [Member]
Restricted cash held as a certificate of deposit	476	476
Warrant liabilities	0	0
Embedded derivative liability	0
Total liabilities	0
Fair Value, Inputs, Level 2 [Member]
Restricted cash held as a certificate of deposit	0	0
Warrant liabilities	232	334
Embedded derivative liability	159
Total liabilities	391
Fair Value, Inputs, Level 3 [Member]
Restricted cash held as a certificate of deposit	0	0
Warrant liabilities	0	$ 0
Embedded derivative liability	0
Total liabilities	$ 0

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements - Fair Value Valuation Assumptions (Details)			3 Months Ended
		Dec. 21, 2023 USD ($)	Mar. 31, 2024 USD ($) yr	Mar. 31, 2023 USD ($)
Non-cash gain on changes in fair value of warrant liabilities			$ (194,000)	$ 0
May 2023 Warrants [Member]
Non-cash gain on changes in fair value of warrant liabilities		$ 200,000
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member]
Total Value			$ 1,600,000
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			1.3
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.72
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.801
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Measurement Input			0.0404
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Measurement Input			0.036
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Measurement Input | yr			5.1
Issuance, May 1, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Measurement Input | yr			2.1
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member]
Total value, embedded	[1]		$ 200,000
Gain, embedded derivative			$ 40,000
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative			1.3
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative			0.75
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative			0.769
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative			0.0541
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative			0
Stockholder Approval, June 9, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative | yr			0.7
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member]
Total Value			$ 1,400,000
Non-cash gain on changes in fair value of warrant liabilities			$ 200,000,000
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Measurement Input			1.3
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Measurement Input			0.68
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Measurement Input			0.776
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Measurement Input			0.0459
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Measurement Input			0.0392
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | Maximum [Member]
Measurement Input			0
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Measurement Input | yr			5
Stockholder Approval, June 9, 2023 [Member] | May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Measurement Input | yr			2
Issuance, December 21, 2023 [Member] | The December 2023 Warrants [Member]
Total Value			$ 400,000
Issuance, December 21, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.25
Issuance, December 21, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.23
Issuance, December 21, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.793
Issuance, December 21, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0388
Issuance, December 21, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Issuance, December 21, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Expected Term [Member]
Measurement Input | yr			5.5
Reporting Date, December 31, 2023 [Member] | The December 2023 Warrants [Member]
Total Value			$ 300,000
Non-cash gain on changes in fair value of warrant liabilities			$ 56,000,000
Reporting Date, December 31, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.25
Reporting Date, December 31, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.2
Reporting Date, December 31, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.793
Reporting Date, December 31, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0385
Reporting Date, December 31, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Reporting Date, December 31, 2023 [Member] | The December 2023 Warrants [Member] | Measurement Input, Expected Term [Member]
Measurement Input | yr			5.5
Reporting Date, March 31, 2024 [Member] | Unsecured Convertible Notes [Member]
Total value, embedded			$ 200,000
Gain, embedded derivative			$ 65,000
Reporting Date, March 31, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative			0.14
Reporting Date, March 31, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative			0.1
Reporting Date, March 31, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative			0.869
Reporting Date, March 31, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative			0.0459
Reporting Date, March 31, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative			0
Reporting Date, March 31, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative | yr			2
Reporting Date, March 31, 2024 [Member] | The December 2023 Warrants [Member]
Total Value			$ 200,000
Non-cash gain on changes in fair value of warrant liabilities			$ 173,000
Reporting Date, March 31, 2024 [Member] | The December 2023 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.25
Reporting Date, March 31, 2024 [Member] | The December 2023 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.1
Reporting Date, March 31, 2024 [Member] | The December 2023 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.923
Reporting Date, March 31, 2024 [Member] | The December 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Measurement Input			0.0421
Reporting Date, March 31, 2024 [Member] | The December 2023 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Reporting Date, March 31, 2024 [Member] | The December 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Measurement Input | yr			5.2
Reporting Date, March 31, 2024 [Member] | March 2024 Warrant [Member]
Total Value			$ 100,000
Non-cash gain on changes in fair value of warrant liabilities			$ 21,000
Reporting Date, March 31, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.14
Reporting Date, March 31, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.1
Reporting Date, March 31, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.869
Reporting Date, March 31, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Measurement Input			0.0421
Reporting Date, March 31, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Reporting Date, March 31, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Measurement Input | yr			5.5
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member]
Total value, embedded			$ 200,000
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative			0.14
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative			0.13
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative			0.869
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative			0.0454
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative			0
Issuance, March 25, 2024 [Member] | Unsecured Convertible Notes [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative | yr			2
Issuance, March 25, 2024 [Member] | March 2024 Warrant [Member]
Total Value			$ 100,000
Issuance, March 25, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.14
Issuance, March 25, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.13
Issuance, March 25, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.869
Issuance, March 25, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0424
Issuance, March 25, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Issuance, March 25, 2024 [Member] | March 2024 Warrant [Member] | Measurement Input, Expected Term [Member]
Measurement Input | yr			5.5
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member]
Total Value			$ 300,000
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			6.3
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.72
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.801
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Measurement Input			0.0473
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Measurement Input			0.0359
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Measurement Input | yr			5.6
Pre-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Measurement Input | yr			1.1
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member]
Total Value			$ 500,000
Non-cash gain on changes in fair value of warrant liabilities			$ 200,000
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			1.5
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.72
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.801
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Measurement Input			0.0473
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Measurement Input			0.0359
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Measurement Input | yr			5.6
Post-amendment [Member] | July 2020, November 2021, September 2022 & November 2022 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Measurement Input | yr			1.1
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member]
Total Value			$ 56,000
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			1.3
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.23
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.793
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Measurement Input			0.0462
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Measurement Input			0.0392
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Measurement Input			4.5
Pre-amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Measurement Input			1.5
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member]
Total Value			$ 200
Non-cash gain on changes in fair value of warrant liabilities			$ 100
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.25
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.23
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.793
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Measurement Input			0.0462
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Measurement Input			0.0392
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Measurement Input			4.5
Post amendment, December 21, 2023 [Member] | The May 2023 Warrants [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Measurement Input			1.5
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value			$ 9,600,000
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			6.3
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.72
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.801
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0491
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Prior to Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input			0.8
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value			$ 11,600,000
Deemed dividend			$ 2,000,000
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			1.3
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.72
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.801
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0491
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
After Ratchet, April 27, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input			0.8
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value	[2]		$ 1,700,000
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			1.3
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.23
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.793
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0543
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Prior to Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input | yr			0.3
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member]
Total Value	[2]		$ 6,700,000
Deemed dividend			$ 5,100,000
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.25
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.23
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Price Volatility [Member]
Measurement Input			0.793
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0543
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
After Ratchet, December 21, 2023 [Member] | Series B Preferred Stock and Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input | yr			0.3
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member]
Total Value	[2]		$ 500,000
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.25
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.13
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Option Volatility [Member]
Measurement Input			0.799
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0551
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
Prior to Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input			0.1
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member]
Total Value	[2]		$ 900,000
Deemed dividend			$ 400,000
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Exercise Price [Member]
Measurement Input			0.14
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Share Price [Member]
Measurement Input			0.13
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Option Volatility [Member]
Measurement Input			0.799
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement Input			0.0551
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement Input			0
After Ratchet, March 24, 2024 [Member] | Series C Preferred Stock [Member] | Measurement Input, Expected Term [Member]
Measurement Input			0.1
Issuance, April 27, 2023 [Member] | Convertible Debt [Member]
Total value, embedded	[1]		$ 200,000
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Exercise Price [Member]
Measurement input, embedded derivative			1.3
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Share Price [Member]
Measurement input, embedded derivative			0.72
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Option Volatility [Member]
Measurement input, embedded derivative			0.801
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Measurement input, embedded derivative			0.0488
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Dividend Rate [Member]
Measurement input, embedded derivative			0
Issuance, April 27, 2023 [Member] | Convertible Debt [Member] | Measurement Input, Expected Term [Member]
Measurement input, embedded derivative | yr			0.8
[1]Adjusted for probability of occurrence.[2]Includes value of incremental shares underlying preferred stock and adjusted for probability of occurrence.

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Prepaid dues and subscriptions	$ 89	$ 85
Prepaid taxes	68	83
Prepaid inventory	4	73
Prepaid insurance	114	66
Other	96	81
Prepaid expenses from discontinued operations	0	(132)
Total prepaid expenses and other current assets	$ 371	$ 256

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Raw materials and supplies	$ 160	$ 1,027
Finished goods	732	2,477
Less: Reserve for excess and obsolete inventory	(229)	(627)
Inventory, net of reserves, from discontinued operations	0	(2,313)
Total inventory, net	$ 663	$ 564

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Depreciation	$ 12	$ 13
Disposal Group, Including Discontinued Operation, Depreciation and Amortization	0	$ 0
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment	$ 0		$ 0

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Property and equipment, at cost	$ 762	$ 760
Less: accumulated depreciation	(685)	(673)
Total property and equipment, net	77	87
Office and Laboratory Equipment [Member]
Property and equipment, at cost	20	20
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	433	431
Leasehold Improvements [Member]
Property and equipment, at cost	$ 152	$ 152

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Contract liabilities (see Note 14)	$ 745	$ 946
Employee payroll and benefits	308	341
Other	213	229
Accrued liabilities from discontinued operations	0	(347)
Total accrued liabilities	$ 1,266	$ 1,169

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Operating lease – expense	$ 100	$ 100
Operating lease from discontinued operations – expense	0	30
Operating lease – included in operating cash flow	76	74
Operating lease from discontinued operations – included in operating cash flow	$ 0	$ 32
Weighted-average remaining lease term (in years) (Year)	3 years 3 months 18 days		4 years
Weighted-average discount rate	5%		5%

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2024	$ 350
2025	439
2026	444
2027	290
Total future minimum lease payments	1,523
Less: Imputed interest	(107)
Total	1,416
Operating lease liability	375	$ 368
Operating lease liability- non-current	1,041	$ 1,108
Total	$ 1,416

Note 9 - Financing Activities (

Note 9 - Financing Activities (Details Textual)					1 Months Ended		3 Months Ended
	Mar. 24, 2024 USD ($) shares	Dec. 21, 2023 USD ($) $ / shares	May 01, 2023 USD ($) $ / shares shares	Apr. 27, 2023	Dec. 31, 2023 USD ($) $ / shares shares	May 31, 2023 USD ($)	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 $ / shares
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.82		$ 1.6	$ 7.7	$ 7.7
Fair Value Adjustment of Warrants							$ (194,000)	$ 0
The 2023 Private Placement [Member]
Debt Issuance Costs, Net			$ 700,000
Other Expenses			400,000
Proceeds From Debenture and Warrant Issuances, Net			3,000,000
Proceeds from Issuance of Warrants			1,600,000
Proceeds from Derivative Instrument, Financing Activities						$ 200,000
Proceeds from Convertible Debt			1,200,000
Unsecured Convertible Notes [Member]
Debt Instrument, Face Amount	$ 525,000
Debt Instrument, Convertible, Number of Equity Instruments	3,750,000
Debt Issuance Costs, Net	$ 130,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	19,000
Other Expenses	$ 111,000
Original Issue Discount Senior Secured Convertible Debentures [Member]
Debt Instrument, Face Amount			3,300,000
Debt Instrument, Convertible, Number of Equity Instruments				2,538,464			1,030,944
Debt Issuance Costs, Net			300,000				$ 48,000
Fair Value Adjustment of Warrants			40,000
Debt Instrument, Unamortized Discount			300,000				$ 293,000
Original Issue Discount Senior Secured Convertible Debentures [Member] | The 2023 Private Placement [Member]
Debt Instrument, Unamortized Discount			$ 300,000
Series D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1,000,000
May 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					2,528,848
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs					$ 100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 1.3
Proceeds from Warrant Exercises					$ 200,000
Fair Value Adjustment of Warrants		$ 200,000
The 2023 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares					2,528,848
Debt Issuance Costs, Net					$ 200,000
Other Expenses					$ 100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 0.25			$ 0.25
Proceeds from Warrant Exercises					$ 600,000
The December 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares							2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares							$ 0.25
Proceeds from Warrant Exercises					$ 400,000
The 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares			5,076,928
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.5
Fair Value Adjustment of Warrants			$ 400,000

Note 10 - Convertible Notes (De

Note 10 - Convertible Notes (Details Textual)				1 Months Ended	3 Months Ended
	Mar. 24, 2024 USD ($) $ / shares	May 01, 2023 USD ($)	Apr. 27, 2023 USD ($) $ / shares	Dec. 31, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 09, 2023 USD ($)
Repayments of Convertible Debt					$ 578,000	$ 0
Fair Value Adjustment of Warrants					(194,000)	0
Amortization of Debt Issuance Costs and Discounts					433,000	$ 0
The 2023 Private Placement [Member]
Proceeds from Convertible Debt		$ 1,200,000
Debt Issuance Costs, Net		700,000
Unsecured Convertible Notes [Member]
Debt Instrument, Face Amount	$ 525,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.14
Debt Instrument, Convertible, Number of Equity Instruments	3,750,000
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 224,000				$ 159,000
Unrealized Gain (Loss) on Derivatives	65,000
Debt Instrument, Interest Rate, Effective Percentage					144%
Debt Issuance Costs, Net	$ 130,000
Original Issue Discount Senior Secured Convertible Debentures [Member]
Debt Instrument, Face Amount		3,300,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 1.3
Debt Instrument, Convertible, Number of Equity Instruments			2,538,464		1,030,944
Debt Instrument, Interest Rate, Effective Percentage					173%
Debt Instrument, Unamortized Discount		300,000			$ 293,000
Debt Instrument, Increase (Decrease), Net			$ (183,000)
Debt Instrument, Redemption Price, Amount Per Month			$ 193,000				$ 193,000
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger			90%
Debt Instrument, Convertible, Threshold Trading Days			10
Debt Instrument, Redemption Price, Percentage			20%
Repayments of Convertible Debt				$ 126,000
Debt Instrument, Default, Interest Rate			18%
Embedded Derivative, Fair Value			$ 209,000					$ 169,000
Fair Value Adjustment of Warrants		40,000
Debt Issuance Costs, Net		300,000			48,000
Amortization of Debt Issuance Costs and Discounts					$ 400,000
Original Issue Discount Senior Secured Convertible Debentures [Member] | The 2023 Private Placement [Member]
Debt Instrument, Unamortized Discount		$ 300,000
Original Issue Discount Senior Secured Convertible Debentures [Member] | Measurement Input, Redemption in Stock [Member]
Debt Instrument, Redemption Price, Amount Per Month			$ 193,000

Note 10 - Convertible Note - Co

Note 10 - Convertible Note - Convertible Notes (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	May 01, 2023
Total Secured Convertible Notes, net	$ 973	$ 1,137
Original Issue Discount Senior Secured Convertible Debentures [Member]
Principal amount	1,314
Unamortized discount for proceeds allocated to embedded derivative liability and May 2023 Warrants	(293)		$ (300)
Unamortized debt issuance costs	(48)		$ (300)
Total Secured Convertible Notes, net	$ 973

Note 10 - Convertible Note - _2

Note 10 - Convertible Note - Contractual Maturity (Details) $ in Thousands	Mar. 31, 2024 USD ($)
Original Issue Discount Senior Secured Convertible Debentures [Member]
Label	$ 1,314

Note 11 - Common Stock Warran_3

Note 11 - Common Stock Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Dec. 21, 2023	May 01, 2023	Sep. 09, 2022	Mar. 31, 2024	Mar. 31, 2023	Mar. 24, 2024	Dec. 31, 2023	Dec. 31, 2022	Nov. 10, 2022	Nov. 30, 2021	Sep. 09, 2020	Jul. 31, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 1.6	$ 7.7		$ 1.82	$ 7.7
Class of Warrant or Right, Exercised During Period (in shares)				0	0
Fair Value Adjustment of Warrants				$ (194)	$ 0
March 2024 Warrant [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.14		$ 0.14
Warrants and Rights, Vesting Period (Month)				6 months
Warrants and Rights Outstanding, Term (Year)				5 years
The December 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.25
The May 2023 B-1 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,538,464
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.3	$ 1.3		1.3
Class of Warrant or Right, Exercised During Period (in shares)	634,616
The May 2023 B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,538,464
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.3		1.3
Class of Warrant or Right, Exercised During Period (in shares)	1,894,232
The 2023 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.25						$ 0.25
May 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							2,528,848
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 1.3
Fair Value Adjustment of Warrants	$ 200
The November 2022 A-1 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		436,510							515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				6.3					$ 6.3
The November 2022 A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		436,510							515,876
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				6.3					$ 6.3
The November 2022 A-1 and A-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3
The Amended November 2022 A-1 and A-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 100
The 2022 Warrant Reprice Transaction [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			327,860
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
September 2022 Warrants Exercisable for 1.50 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		238,574
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 46
The November 2021 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		535,716								1,071,434
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				6.3						$ 18.55
Amended November 2021 Warrants Exercisable for 6.50 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
Class of Warrant or Right, Exercised During Period (in shares)			267,860
Fair Value Adjustment of Warrants			$ 1,500
Amended November 2021 Warrants Exercisable for 1.50 [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 100
The July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											137,145	197,105
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 57.75								$ 57.75
Amended July 2020 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		77,145
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.3	$ 6.3
Class of Warrant or Right, Exercised During Period (in shares)			60,000
Fair Value Adjustment of Warrants		$ 14,000	$ 400
The 2023 Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		5,076,928
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.5
Fair Value Adjustment of Warrants		$ 400

Note 11 - Common Stock Warran_4

Note 11 - Common Stock Warrants - Outstanding Warrants (Details) - $ / shares shares in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Outstanding warrants (in shares)	7,382,447	2,305,519
Outstanding warrants, weighted-average exercise price (in dollars per share)	$ 1.82	$ 7.7
Warrants granted (in shares)	1,000,000	0
Warrants granted, weighted average exercise price (in dollars per share)	$ 0.14	$ 0
Warrants exercised (in shares)	0	0
Warrants exercised, weighted-average exercise price (in dollars per share)	$ 0	$ 0
Warrants expired (in shares)	0	0
Warrants expired, weighted average exercise price (in dollars per share)	$ 0	$ 0
Warrants exercised (in shares)	0	0
Outstanding warrants (in shares)	8,382,447	2,305,519
Outstanding warrants, weighted-average exercise price (in dollars per share)	$ 1.6	$ 7.7

Note 11 - Common Stock Warran_5

Note 11 - Common Stock Warrants - Warrants Outstanding (Details) - $ / shares shares in Thousands	Mar. 31, 2024	Mar. 24, 2024	Dec. 31, 2023	Dec. 21, 2023	May 01, 2023	Mar. 31, 2023	Dec. 31, 2022	Nov. 10, 2022	Nov. 30, 2021	Jul. 31, 2020
Exercise price (in dollars per share)	$ 1.6		$ 1.82			$ 7.7	$ 7.7
Warrants outstanding (in shares)	8,382,447		7,382,447			2,305,519	2,305,519
The 2019 Ladenburg Warrants [Member]
Exercise price (in dollars per share)	$ 34.65
Expiration date	Aug. 08, 2024
Warrants outstanding (in shares)	4,799
The July 2020 Warrants [Member]
Exercise price (in dollars per share)	$ 57.75									$ 57.75
Expiration date	Jan. 22, 2026
Warrants outstanding (in shares)	59,960
The Amended July 2020 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Jan. 22, 2026
Warrants outstanding (in shares)	77,145
TLF Bio Innovation 2021 Warrants [Member]
Exercise price (in dollars per share)	$ 23.51
Expiration date	Jan. 15, 2026
Warrants outstanding (in shares)	429
The November 2021 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3								$ 18.55
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	267,858
The Amended November 2021 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	535,716
The September 2022 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	89,286
The Amended September 2022 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Sep. 11, 2028
Warrants outstanding (in shares)	238,574
The November 2022 A-1 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3							$ 6.3
Expiration date	Nov. 20, 2028
Warrants outstanding (in shares)	79,366
The Amended November 2022 A-1 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	Nov. 20, 2028
Warrants outstanding (in shares)	436,510
The November 2022 A-2 Warrants [Member]
Exercise price (in dollars per share)	$ 6.3							$ 6.3
Expiration date	May 20, 2024
Warrants outstanding (in shares)	79,366
The Amended November 2022 A-2 Warrants [Member]
Exercise price (in dollars per share)	$ 1.5
Expiration date	May 20, 2024
Warrants outstanding (in shares)	436,510
The May 2023 B-1 Warrants [Member]
Exercise price (in dollars per share)	$ 1.3			$ 1.3	$ 1.3
Expiration date	Jun. 09, 2028
Warrants outstanding (in shares)	1,903,848
The May 2023 B-2 Warrants [Member]
Exercise price (in dollars per share)	$ 1.3				$ 1.3
Expiration date	Jun. 09, 2025
Warrants outstanding (in shares)	644,232
The December 2023 Warrants [Member]
Exercise price (in dollars per share)	$ 0.25
Expiration date	Jun. 21, 2029
Warrants outstanding (in shares)	2,528,848
March 2024 Warrant [Member]
Exercise price (in dollars per share)	$ 0.14	$ 0.14
Warrants outstanding (in shares)	1,000,000

Note 11 - Common Stock Warran_6

Note 11 - Common Stock Warrants - Reconciliation of Common Stock Warrant Liabilities (Details) - Warrant Liability [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Fair value of warrant liability, balance	$ 334
Fair value of warrant liability, balance	232
The December 2023 Warrants [Member]
Decrease in fair value of warrants	(173)
March 2024 Warrant [Member]
Decrease in fair value of warrants	(21)
Fair value of warrant liabilities recognized	$ 92

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Details Textual) $ / shares in Units, $ in Millions						1 Months Ended
	Mar. 27, 2024 $ / shares shares	Dec. 21, 2023 USD ($) $ / shares	Apr. 27, 2023 USD ($) $ / shares	Sep. 09, 2022 USD ($) $ / shares shares	Oct. 29, 2021 shares	Mar. 31, 2024 USD ($) $ / shares shares	Jan. 29, 2024 $ / shares	Dec. 31, 2023 shares	Mar. 31, 2023 $ / shares shares
Common Stock, Shares Authorized (in shares)						150,000,000		150,000,000
Preferred Stock, Shares Authorized (in shares)						5,000,000		5,000,000
Preferred Stock, Convertible, Shares Issuable (in shares)						1,000
May 2023 Warrants [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 1.3
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding (in shares)						1,000		6,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 6.3				$ 0.25
Preferred Stock, Change in Conversion Price, Income Statement Impact | $		$ 4.5		$ 5.7
Series B Preferred Stock [Member] | Minimum [Member]
Preferred Stock, Convertible, Conversion Ratio							75
Series B Preferred Stock [Member] | Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 1.3		$ 14
Series B Preferred Stock [Member] | Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.25		$ 6.3
Series B Preferred Stock [Member] | The 2021 Private Placement Program [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)						3,616,000			1,847,580
Stock Issued During Period, Shares, New Issues (in shares)					15,000
Preferred Stock, Shares Outstanding (in shares)						904			11,620
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares						$ 0.25			$ 6.3
Series B Preferred Stock [Member] | The 2023 Private Placement [Member]
Preferred Stock, Change in Conversion Price, Income Statement Impact | $			$ 1.8
Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,250
Preferred Stock, Shares Outstanding (in shares)						1,000		1,000
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.14		$ 6.3
Preferred Stock, Change in Conversion Price, Income Statement Impact | $		$ 0.5				$ 0.4
Series C Preferred Stock [Member] | Minimum [Member]
Preferred Stock, Convertible, Conversion Ratio	75
Series C Preferred Stock [Member] | Previously Reported [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 1.3				$ 0.25
Series C Preferred Stock [Member] | Revision of Prior Period, Adjustment [Member]
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares		$ 0.25				$ 0.14
Series C Preferred Stock [Member] | The 2023 Private Placement [Member]
Preferred Stock, Change in Conversion Price, Income Statement Impact | $			$ 194
Series C Preferred Stock [Member] | The 2022 Private Placement [Member]
Preferred Stock, Convertible, Shares Issuable (in shares)						5,192,961			357,750
Stock Issued During Period, Shares, New Issues (in shares)				3,250
Preferred Stock, Shares Outstanding (in shares)						727			2,250
Preferred Stock, Convertible, Conversion Price (in dollars per share) | $ / shares						$ 0.14			$ 6.3

Note 13 - Equity-based Compen_3

Note 13 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended
	Mar. 31, 2023	Mar. 31, 2017	Oct. 31, 2007	Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)				0	0
Proceeds from Stock Options Exercised				$ 0	$ 0
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 100
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 4 months 28 days
Share-Based Payment Arrangement, Expense				$ 60	$ 75
Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				0	0
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				0	3,650
Restricted Stock [Member] | Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				0
Share-Based Payment Arrangement, Expense				$ 13	$ 0
Restricted Stock [Member] | Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				0	0
Share-Based Payment Arrangement, Expense				$ 47	$ 75
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)			10 years
The 2017 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		66,243
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock		4%
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	81,417
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				179,585
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum		10%
The 2017 Omnibus Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		4 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		100%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Incentive Stock Options (ISOs) [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent		110%

Note 13 - Equity-based Compen_4

Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Outstanding awards (in shares)		125
Outstanding, weighted-average exercise price (in dollars per share)		$ 31.15
Outstanding, weighted-average remaining contractual life (Year)	6 years 9 months 18 days	7 years 3 months 18 days
Outstanding, aggregate intrinsic value	$ 1	$ 1
Options forfeited/cancelled (in shares)	(8)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share)	$ 20.36
Outstanding awards (in shares)	117
Outstanding, weighted-average exercise price (in dollars per share)	$ 31.91
Vested and expected to vest (in shares)	111
Vested and expected to vest, weighted-average exercise price (in dollars per share)	$ 33.17
Vested and expected to vest, weighted-average remaining contractual life (Year)	6 years 8 months 12 days
Vested and expected to vest, aggregate intrinsic value	$ 1
Vested and exercisable (in shares)	62
Exercisable, weighted-average exercise price (in dollars per share)	$ 56.86
Exercisable, weighted-average remaining contractual life (Year)	5 years

Note 13 - Equity-based Compen_5

Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member]	3 Months Ended
	Mar. 31, 2024 $ / shares
Expected price volatility	154.49%
Expected term (Year)	6 years 7 months 28 days
Risk-free interest rate	3.41%
Dividend yield	0%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 2.37

Note 13 - Equity-based Compen_6

Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock-based compensation expense	$ 60	$ 75
Research and Development Expense [Member]
Stock-based compensation expense	4	6
Selling and Marketing Expense [Member]
Stock-based compensation expense	26	15
General and Administrative Expense [Member]
Stock-based compensation expense	$ 30	$ 54

Note 14 - Distribution Agreem_3

Note 14 - Distribution Agreements (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Revenue from Contract with Customer, Including Assessed Tax	$ 2,631	$ 2,339
Contract with Customer, Liability	745		$ 728
DERMAdoctor [Member] | Costco and Others [Member]
Revenue from Contract with Customer, Including Assessed Tax	55	92
Contract with Customer, Liability	700		$ 700
Avenova Direct [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 1,700	$ 1,600

Note 14 - Distribution Agreem_4

Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($)
Balance at December 31, 2023	$ 946
Less discontinued operations	(218)
Continuing operations balance at December 31, 2023	728
Current period	52
Payments and customer credits issued	(35)
Balance	745
Chargebacks, Discounts for Prompt, Payment, and Other [Member]
Balance at December 31, 2023	913
Less discontinued operations	(218)
Continuing operations balance at December 31, 2023	695
Current period	26
Payments and customer credits issued	(2)
Balance	719
Other Customer Fees [Member]
Balance at December 31, 2023	12
Less discontinued operations	0
Continuing operations balance at December 31, 2023	12
Current period	8
Payments and customer credits issued	(7)
Balance	13
Rebates [Member]
Balance at December 31, 2023	21
Less discontinued operations	0
Continuing operations balance at December 31, 2023	21
Current period	18
Payments and customer credits issued	(26)
Balance	$ 13

Note 15 - Employee Benefit Pl_2

Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
The 401K Plan Contribution Level One [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	3%
The 401K Plan Contribution Level Two [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	2%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 24	$ 23
Disposal Group, Including Discontinued Operations, Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 9

Note 16 - Segment Reporting (De

Note 16 - Segment Reporting (Details Textual)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Number of Reportable Segments	1	2

Note 17 - Divestiture and Dis_3

Note 17 - Divestiture and Discontinued Operations (Details Textual) - USD ($) $ in Thousands		3 Months Ended
	Mar. 25, 2024	Mar. 31, 2024	Mar. 31, 2023
Proceeds from Divestiture of Businesses		$ 1,070	$ 0
Discontinued Operations, Disposed of by Sale [Member] | DERMAdoctor [Member]
Disposal Group, Including Discontinued Operation, Percentage Sold	100%
Proceeds from Divestiture of Businesses	$ 1,100

Note 17 - Divestiture and Dis_4

Note 17 - Divestiture and Discontinued Operations - Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Cash and cash equivalents	$ 0		$ 206
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)	0		2,313
Prepaid expenses and other current assets	0		132
Total current assets, discontinued operations	0		2,730
Total assets, discontinued operations	0		19
Accrued liabilities	0		347
Total current liabilities, discontinued operations	0		698
Net loss from discontinued operations	(124)	$ (394)
Net loss from discontinued operations	(124)	(394)
Accounts receivable	54	(250)
Inventory	(107)	(80)
Prepaid expenses and other current assets	(115)	(45)
Operating lease right-of-use assets	84	59
Other assets	1	(6)
Accounts payable and accrued liabilities	308	(74)
Operating lease liabilities	(60)	(34)
DERMAdoctor [Member] | Discontinued Operations, Disposed of by Sale [Member]
Cash and cash equivalents			206
Accounts receivable, net of allowance for credit losses ($0 at December 31, 2023)			79
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($363 at December 31, 2023)			2,313
Prepaid expenses and other current assets			132
Total current assets, discontinued operations			2,730
Other assets			19
Total assets, discontinued operations			2,749
Accounts payable			224
Accrued liabilities			347
Operating lease liabilities			127
Total current liabilities, discontinued operations			698
Total liabilities, discontinued operations			$ 698
Product revenue, net	717	785
Cost of goods sold	493	449
Gross profit	224	336
Research and development	2	16
Sales and marketing	292	417
General and administrative	48	292
Total operating expenses	342	725
Operating loss	(118)	(389)
Other expense, net	(6)	(5)
Net loss from discontinued operations	(124)	(394)
Net loss from discontinued operations	(124)	(394)
Amortization of intangible assets	0	38
Accounts receivable	(262)	(112)
Inventory	183	(280)
Prepaid expenses and other current assets	(4)	89
Operating lease right-of-use assets	0	28
Other assets	15	9
Accounts payable and accrued liabilities	63	227
Operating lease liabilities	(31)	(29)
Net cash used in operating activities, discontinued operations	(160)	(424)
Cash transferred to New Age Investments, LLC	(46)	0
Net cash used in investing activities, discontinued operations	(46)	0
Net decrease in cash and cash equivalents, discontinued operations	$ (206)	$ (424)

Note 17 - Divestiture and Dis_5

Note 17 - Divestiture and Discontinued Operations - Discontinued Operations (Details) (Parentheticals) - DERMAdoctor [Member] - Discontinued Operations, Disposed of by Sale [Member] $ in Thousands	Dec. 31, 2023 USD ($)
Allowance for credit losses	$ 0
Reserve	$ 363

Note 18 - Subsequent Events (De

Note 18 - Subsequent Events (Details Textual) - Subsequent Event [Member]	1 Months Ended
	May 09, 2024 shares
Conversion of Series B Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)	273
Conversion of Stock, Shares Issued (in shares)	1,092,000
Conversion of Series C Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)	660
Conversion of Stock, Shares Issued (in shares)	4,714,380